Important note

This AI stock analysis for Tarsus Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Tarsus Pharmaceuticals - AI Stock Analysis

Analysis generated January 16, 2025

Tarsus Pharmaceuticals is a biopharmaceutical company dedicated to revolutionizing the treatment landscape for a range of diseases. With a focus on developing innovative therapeutics, Tarsus has achieved a reputation for pushing the boundaries in research and development. The company aims to address unmet medical needs through a combination of clinical expertise, innovative treatment modalities, and strategic business operations.

Fundamental Analysis

In the latest quarter, Tarsus Pharmaceuticals reported revenue of $48M. This is a notable increase of 17.90% compared to the previous quarter. Year-over-year, the revenue has surged by an astounding 2,471.78%, indicating strong growth and expanding market presence.

The company's net income for the last quarter was $23M. This represents a quarterly growth of 29.65% and a year-over-year increase of 40.18%. This upward trend in net income is a positive sign of the company's profitability and operational efficiency.

EBITDA for the last quarter was $25M, which constitutes an increase of 24.52% compared to the quarter before it. Year-over-year, the EBITDA has grown by 34.98%. This suggests consistent operational strength and efficient cost management.

Technical Analysis

The current stock price of Tarsus Pharmaceuticals is $46.92. Despite a short-term decrease of 9.30% compared to a month ago, the stock has shown an impressive increase of 100.34% compared to a year ago. This long-term upward trend signifies robust investor confidence.

However, the technical indicators suggest a bearish short-term trend. The current SMA10 is $50.85, lower than the previous SMA10 of $51.77, indicating a potential downward shift in price movement. Additionally, with an RSI of 74.7, the stock appears to be in an overbought condition, which could further imply a bearish sentiment in the short term.

Alternative Data Analysis

Job postings on popular job boards reveal that Tarsus Pharmaceuticals has 23 open positions, a 130% increase over the past couple of months. This surge suggests an expanding workforce, indicative of growth and forward-moving business strategies. Additionally, employee sentiment is very positive, with 100% of employees having a positive business outlook, reflecting a healthy internal environment.

Customer acquisition metrics are also favorable. The company's website has seen an estimated 24,000 visitors, up by 33% in the last couple of months. This increased traffic is a bullish sign pointing toward potential customer growth.

Customer engagement on social media platforms is steady but revealing of burgeoning interest. On Instagram, followers have increased by 4% to 1,100, while the Twitter following remains stable at 610.

AltIndex’s AI score for Tarsus Pharmaceuticals stands at 66, which is classified as a buy signal, integrating fundamental, technical, and alternative data analyses.

Conclusion and Recommendation

Tarsus Pharmaceuticals is demonstrating robust fundamental growth, evidenced by significant increases in revenue, net income, and EBITDA. Despite a short-term bearish technical outlook, the stock has shown long-term strength and potentially attractive valuations.

Alternative data analysis paints an optimistic picture of the company's future prospects, supported by increased job postings, positive employee sentiment, and growing web traffic and social media engagement.

Given the strong fundamental performance, favorable alternative data indicators, and long-term upward trend, the stock is rated as a buy. Investors should consider the potential for volatility in the short term but may find significant value for long-term holdings.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.